Compare KLA Corp. (KLAC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Viatris Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: KLA Corp. is far larger — about 12.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Viatris Inc for 57 Days on average.
| KLAC | VTRS | |
|---|---|---|
Market Cap | $256.72B | $20.03B |
Volume | 9,970,753 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $301.71 | $18.27 |
52-Week Low | $98.28 | $9.74 |
Typical Hold Time | 60 Days | 57 Days |
Enterprise Value | $257.97B | $32.15B |
Dividend Yield | 0.47% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $195.57, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $193. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, revenue growth accelerating to $12.16B in 2025, and exceptional profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57B backlog and competitive positioning against AMAT and ASML.
KLA presents a compelling growth opportunity with analyst consensus price target of $223.88 (14.5% upside) and strong institutional support, though elevated valuation ratios (P/E 53.75, P/S 19.12) and semiconductor cycle sensitivity warrant caution. The stock's outlook remains positive driven by AI infrastructure spending and advanced packaging growth, with key risks including competition intensity and potential margin pressure from increased investments.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
